As a legitimate generic version of Lorlatinib officially approved for marketing by the Lao Ministry of Health, LORLADX (100mg×30 tablets/box) manufact···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 198
Against the backdrop of prohibitively high targeted drug costs that deter many patients, the lorlatinib generic (trade name LORLADX) launched by Lao B···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 209
Lorlatinib (formerly known as lorlatinib), as a third-generation dual-target small-molecule inhibitor of ALK and ROS1, exhibits potent inhibitory effe···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 219
As the generic version of Lusutrombopag launched by Big Bear Pharmaceutical in Laos, LUTRODX provides a new treatment option for adult patients with c···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 196
Lusutrombopag is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) that promotes platelet production by activating the thrombopoietin re···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 188
BigBear Pharma (BIGBEARPharma) in Laos announced that its generic version of Lusutrombopag, LUTRODX, has received marketing authorization from the Lao···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 196
Binimetinib, as an ATP-noncompetitive reversible MEK1/2 inhibitor, plays an important role in the treatment of unresectable or metastatic melanoma wit···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 179
For many oncology patients facing prohibitively high targeted therapy costs, the Lao Dabang version of Binimetinib undoubtedly brings new hope—this ge···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 177
BigBearPharma (Laos) has announced that its generic version of Binimetinib has officially received approval from the Lao Ministry of Health, under the···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 174
Based on the durable efficacy and intracranial activity demonstrated in the TRIDENT-1 clinical trial, the next-generation ROS1/TRK inhibitor repotrect···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 168
When the original drug Repotrectinib, with a monthly treatment cost of tens of thousands of dollars, puts it out of reach for many patients, the gener···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 148
Repotrectinib, as a next-generation ROS1 and NTRK targeted inhibitor, can effectively overcome multiple resistance mutations to other tyrosine kinase ···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 183
Cabozantinib, known as the "troublemaker" among targeted therapies, can simultaneously inhibit multiple key targets including VEGFR, C-MET, ···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 189
In the generic cabozantinib market, the capsule formulation launched by Lao Big Bear Pharmaceutical is highly favored for its affordable price and rel···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 201
The generic cabozantinib produced by BigBearPharma in Laos, marketed under the brand name CABODX, offers a new regulatory-approved treatment option fo···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 184
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos